The WHO and Why of HIV Vaccine Trials

var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www."); document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E")); ion" CONTENT="John Moore of the Aaron Diamond AIDS Research Center and Roy Anderson of the Centre for the Epidemiology of Infectious Diseases discuss the reasoning behind the World Health Organization (WHO) advisory committee s decision to approve Phase III HIV vaccine trials in developing countries. Ninety percent of the 16 millio"> The WHO and Why of HIV Vaccine Trials < > // var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www."); document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E")); > < > // var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www."); document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E")); >

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

The WHO and Why of HIV Vaccine Trials

Nature (11/24/94) Vol. 372, No. 6504, P. 313
Moore, John; Anderson, Roy

John Moore of the Aaron Diamond AIDS Research Center and Roy Anderson of the Centre for the Epidemiology of Infectious Diseases discuss the reasoning behind the World Health Organization (WHO) advisory committee's decision to approve Phase III HIV vaccine trials in developing countries. Ninety percent of the 16 million people estimated by the WHO to be HIV-infected live in poor communities in the developing world. While the main concern of the committee members was that the products would not work, clinicians and epidemiologists argued that the only way to determine efficacy is to run an efficacy trial. The WHO committee concluded that, ultimately, any decision to go ahead with a trial of any product must be made by the host country for the trial. Phase I/II safety trials should precede a Phase III trial. The panel also stated that the specific HIV-1 subtypes among the proposed trial population should be a significant consideration, as should counseling of the trial populations about the potential risks of vaccination and the necessity of following safe sex practices. The WHO committee emphasized a long-term commitment to AIDS vaccine development and testing worldwide.

941220
AD942275

Copyright © 1994 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .